#	Pagina
attuale pagina	/open-h2020/projects/224488/index.html
-1	/open-h2020/per-topic/scandinavia/list/index.html

Opendata, web and dolomites

VISIOCYT

VISIOCYT SCREENING: A DISRUPTIVE ARTIFICIAL INTELLIGENCE SOLUTION FOR BLADDER CANCER SCREENING

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

VISIOCYT project word cloud

Explore the words cloud of the VISIOCYT project. It provides you a very rough idea of what is the project "VISIOCYT" about.

laboratories labs reproducible diagnosis business expertise combines ing clinical cytology besides standard perform rate ivd tumour almost exposed market price image depends vitro global 65 200 solutions risk screening incidence detection drops 2023 automated vitadx 2018 smokers cancer sme treatment fast identification readily deaths algorithms lt artificial solution few intelligence tool software 2 workers patients device regular gt background people diagnostic survival french accuracy centralized symptoms equipped images predict appear tumours chemicals 95 easier bladder cagr certain 5 skills invasive living 75 disease throughput visiocyt locations cheaper stages customers programs time former billion 5th scientific 58 polluted grade medical classified stage dying

Project "VISIOCYT" data sheet

The following table provides information about the project.

Coordinator	VITADX INTERNATIONAL Organization address address: 74 F RUE DE PARIS city: RENNES postcode: 35000 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	https://vitadx.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2019
Duration (year-month-day)	from 2019-06-01 to 2019-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	VITADX INTERNATIONAL VITADX INTERNATIONAL Organization address address: 74 F RUE DE PARIS city: RENNES postcode: 35000 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (RENNES)	coordinator	50˙000.00

Map

Project objective

Bladder cancer is the 5th most common cancer in Europe, with almost 200,000 new cases and 65,000 deaths estimated in 2018. People at high risk for developing this disease include smokers, former smokers, people living in polluted areas, and workers exposed to certain chemicals. The risk of dying from bladder cancer depends on the time of diagnosis and the tumour’s grade: the 5-year survival rate is >95% in early stage cancer, but it drops to <5% in late stage tumours. Besides increased survival, the identification of bladder cancer at its early stages is also associated with easier, less invasive, and cheaper treatment. Given the importance of early detection and the high incidence of bladder cancer, screening programs for this disease are needed. However, there is no screening tool currently available for bladder cancer. As a solution, VitaDX is developing VisioCyt Screening: a software that combines artificial intelligence algorithms with standard cytology analysis to predict with high accuracy the presence of bladder cancer in patients, even before symptoms appear. Being a software that analyses images obtained through regular clinical procedures, VisioCyt Screening can be readily implemented in centralized labs, resulting in a fast, easy-to-use, reproducible, automated, and high-throughput solution at a low price. VisioCyt Screening can be classified as an in-vitro diagnostic (IVD) medical device. The global IVD market was estimated at €58 billion in 2018, and is expected to reach €75.2 billion by 2023, with a CAGR rate of 5.2%. In this market, centralized laboratories, which perform large numbers of analyses in few locations and are equipped with the automated systems required by the VisioCyt solution, represent the most relevant target users and customers for VitaDX. VitaDX is a French SME that combines a strong scientific and clinical background with software and image processing skills and business expertise to develop new diagnostic solutions for cancer.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VISIOCYT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VISIOCYT" are provided by the European Opendata Portal: CORDIS opendata.